226 related articles for article (PubMed ID: 35929603)
1. Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy.
Murphy KJ; Zhu J; Trpceski M; Pereira BA; Timpson P; Herrmann D
Biochem Soc Trans; 2022 Aug; 50(4):1129-1141. PubMed ID: 35929603
[TBL] [Abstract][Full Text] [Related]
2. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma.
Scianò F; Terrana F; Pecoraro C; Parrino B; Cascioferro S; Diana P; Giovannetti E; Carbone D
Future Med Chem; 2024 Feb; 16(3):271-289. PubMed ID: 38269431
[TBL] [Abstract][Full Text] [Related]
3. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
[TBL] [Abstract][Full Text] [Related]
4. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
[TBL] [Abstract][Full Text] [Related]
5. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
Roy-Luzarraga M; Reynolds LE; de Luxán-Delgado B; Maiques O; Wisniewski L; Newport E; Rajeeve V; Drake RJG; Gómez-Escudero J; Richards FM; Weller C; Dormann C; Meng YM; Vermeulen PB; Saur D; Sanz-Moreno V; Wong PP; Géraud C; Cutillas PR; Hodivala-Dilke K
Cancer Res; 2022 May; 82(10):1909-1925. PubMed ID: 35350066
[TBL] [Abstract][Full Text] [Related]
7. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Kanteti R; Mirzapoiazova T; Riehm JJ; Dhanasingh I; Mambetsariev B; Wang J; Kulkarni P; Kaushik G; Seshacharyulu P; Ponnusamy MP; Kindler HL; Nasser MW; Batra SK; Salgia R
Cancer Biol Ther; 2018 Apr; 19(4):316-327. PubMed ID: 29303405
[TBL] [Abstract][Full Text] [Related]
8. Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma.
Decaup E; Rochotte J; Pyronnet S; Bousquet C; Jean C
Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):246-248. PubMed ID: 27939096
[TBL] [Abstract][Full Text] [Related]
9. Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade.
Lander VE; Belle JI; Kingston NL; Herndon JM; Hogg GD; Liu X; Kang LI; Knolhoff BL; Bogner SJ; Baer JM; Zuo C; Borcherding NC; Lander DP; Mpoy C; Scott J; Zahner M; Rogers BE; Schwarz JK; Kim H; DeNardo DG
Cancer Discov; 2022 Dec; 12(12):2774-2799. PubMed ID: 36165893
[TBL] [Abstract][Full Text] [Related]
10. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
Canel M; Sławińska AD; Lonergan DW; Kallor AA; Upstill-Goddard R; Davidson C; von Kriegsheim A; Biankin AV; Byron A; Alfaro J; Serrels A
Gut; 2023 Dec; 73(1):131-155. PubMed ID: 36977556
[TBL] [Abstract][Full Text] [Related]
11. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
Le Large TYS; Bijlsma MF; El Hassouni B; Mantini G; Lagerweij T; Henneman AA; Funel N; Kok B; Pham TV; de Haas R; Morelli L; Knol JC; Piersma SR; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
J Exp Clin Cancer Res; 2021 Mar; 40(1):91. PubMed ID: 33750427
[TBL] [Abstract][Full Text] [Related]
12. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Zhang J; He DH; Zajac-Kaye M; Hochwald SN
Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
[TBL] [Abstract][Full Text] [Related]
13. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer.
Zaghdoudi S; Decaup E; Belhabib I; Samain R; Cassant-Sourdy S; Rochotte J; Brunel A; Schlaepfer D; Cros J; Neuzillet C; Strehaiano M; Alard A; Tomasini R; Rajeeve V; Perraud A; Mathonnet M; Pearce OM; Martineau Y; Pyronnet S; Bousquet C; Jean C
EMBO Mol Med; 2020 Nov; 12(11):e12010. PubMed ID: 33025708
[TBL] [Abstract][Full Text] [Related]
14. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
[TBL] [Abstract][Full Text] [Related]
15. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status.
Murphy KJ; Reed DA; Vennin C; Conway JRW; Nobis M; Yin JX; Chambers CR; Pereira BA; Lee V; Filipe EC; Trpceski M; Ritchie S; Lucas MC; Warren SC; Skhinas JN; Magenau A; Metcalf XL; Stoehr J; Major G; Parkin A; Bidanel R; Lyons RJ; Zaratzian A; Tayao M; Da Silva A; Abdulkhalek L; ; ; Gill AJ; Johns AL; Biankin AV; Samra J; Grimmond SM; Chou A; Goetz JG; Samuel MS; Lyons JG; Burgess A; Caldon CE; Horvath LG; Daly RJ; Gadegaard N; Wang Y; Sansom OJ; Morton JP; Cox TR; Pajic M; Herrmann D; Timpson P
Sci Adv; 2021 Oct; 7(40):eabh0363. PubMed ID: 34586840
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
[TBL] [Abstract][Full Text] [Related]
17. FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer.
Davidson C; Taggart D; Sims AH; Lonergan DW; Canel M; Serrels A
Br J Cancer; 2022 Nov; 127(10):1893-1905. PubMed ID: 36138073
[TBL] [Abstract][Full Text] [Related]
18. FAK and paxillin, two potential targets in pancreatic cancer.
Kanteti R; Batra SK; Lennon FE; Salgia R
Oncotarget; 2016 May; 7(21):31586-601. PubMed ID: 26980710
[TBL] [Abstract][Full Text] [Related]
19. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.
Erkan M; Hausmann S; Michalski CW; Fingerle AA; Dobritz M; Kleeff J; Friess H
Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):454-67. PubMed ID: 22710569
[TBL] [Abstract][Full Text] [Related]
20. Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy.
Vennin C; Rath N; Pajic M; Olson MF; Timpson P
Small GTPases; 2020 Jan; 11(1):45-52. PubMed ID: 28972449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]